Global Blood Therapeutics Stock Market Capitalization
| GBTDelisted Stock | USD 68.49 0.00 0.00% |
Global Blood Therapeutics fundamentals help investors to digest information that contributes to Global Blood's financial success or failures. It also enables traders to predict the movement of Global Stock. The fundamental analysis module provides a way to measure Global Blood's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Global Blood stock.
Global |
Global Blood Therapeutics Company Market Capitalization Analysis
Global Blood's Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Current Global Blood Market Capitalization | 4.41 B |
Most of Global Blood's fundamental indicators, such as Market Capitalization, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Global Blood Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
CompetitionBased on the recorded statements, the market capitalization of Global Blood Therapeutics is about 4.41 B. This is 65.92% lower than that of the Healthcare sector and 6.98% lower than that of the Biotechnology industry. The market capitalization for all United States stocks is 76.83% higher than that of the company.
Global Market Capitalization Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Global Blood's direct or indirect competition against its Market Capitalization to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Global Blood could also be used in its relative valuation, which is a method of valuing Global Blood by comparing valuation metrics of similar companies.Global Blood is currently under evaluation in market capitalization category among related companies.
Global Fundamentals
| Return On Equity | -124.53 | |||
| Return On Asset | -23.82 | |||
| Profit Margin | (146.82) % | |||
| Operating Margin | (137.33) % | |||
| Current Valuation | 2.24 B | |||
| Shares Outstanding | 64.45 M | |||
| Shares Owned By Insiders | 2.72 % | |||
| Shares Owned By Institutions | 97.28 % | |||
| Number Of Shares Shorted | 9.23 M | |||
| Price To Earning | (13.97) X | |||
| Price To Book | 10.19 X | |||
| Price To Sales | 20.93 X | |||
| Revenue | 210.87 M | |||
| Gross Profit | 191.43 M | |||
| EBITDA | (283.56 M) | |||
| Net Income | (309.58 M) | |||
| Cash And Equivalents | 553.42 M | |||
| Cash Per Share | 8.50 X | |||
| Total Debt | 659.05 M | |||
| Debt To Equity | 4.92 % | |||
| Current Ratio | 8.52 X | |||
| Book Value Per Share | 6.72 X | |||
| Cash Flow From Operations | (249.41 M) | |||
| Short Ratio | 5.38 X | |||
| Earnings Per Share | (4.04) X | |||
| Price To Earnings To Growth | (0.19) X | |||
| Number Of Employees | 457 | |||
| Beta | 0.86 | |||
| Market Capitalization | 4.41 B | |||
| Total Asset | 153.07 M | |||
| Retained Earnings | (758.36 M) | |||
| Working Capital | 140.1 M | |||
| Current Asset | 150.82 M | |||
| Current Liabilities | 10.72 M | |||
| Z Score | -4.3 |
About Global Blood Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Global Blood Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Global Blood using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Global Blood Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Global Blood in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Global Blood's short interest history, or implied volatility extrapolated from Global Blood options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Global Blood Therapeutics information on this page should be used as a complementary analysis to other Global Blood's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Other Consideration for investing in Global Stock
If you are still planning to invest in Global Blood Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Global Blood's history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |